Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.84 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.84 |
| ▸ | KIT | P10721 | 2/20 | 0.84 |
| ▸ | SRC | P12931 | 2/20 | 0.84 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.84 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.84 |
| ▸ | CIT | O14578 | 1/20 | 0.84 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.84 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.84 |
| ▸ | STK17B | O94768 | 1/20 | 0.84 |
| ▸ | STK10 | O94804 | 1/20 | 0.84 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | LCK | P06239 | 1/20 | 0.84 |
| ▸ | FYN | P06241 | 1/20 | 0.84 |
| ▸ | YES1 | P07947 | 1/20 | 0.84 |
| ▸ | LYN | P07948 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30415948 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL14190829 | 0.93 | EGFR (0.73) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29655741 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL54837 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29623482 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29368458 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2141065 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2052123 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL30436576 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL26055564 | 0.90 | EGFR (0.78) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130137774-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-8252749-B2 | Methods, kits, and compositions for generating new hair follicles and growing hair | FOLLICA, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-8017735-B2 | Comprising one or more binding compositions comprising a member selected from a light chain amino acid sequence which comprises CDR-L1 and a heavy chain amino acid sequence which comprises CDR-H1 in association with one or more chemotherapeutic agents; cancer therapy | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110130706-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20100120768-A1 | METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR | LIGHTHOUSE CAPITAL PARTNERS VI, L.P. | 2010-05-13 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | EGFR 104/4885ERBB2 173/4885ERBB4 225/4885 |
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | EGFR 87/4885ERBB2 129/4885ERBB4 690/4885 |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | EGFR 144/4885ERBB2 297/4885ERBB4 146/4885 |
| US-20110014117-A1 | ANTI-IGF1R | IGF1R, IGFBP1, IGFBP2 | EGFR 21/4885ERBB2 24/4885ERBB4 57/4885 |
| US-20130137774-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885ERBB4 4/4885 |
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885ERBB4 6/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | EGFR 4244/4885ERBB2 3959/4885ERBB4 4274/4885 |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, KLK3, CD44 | EGFR 60/4885ERBB2 184/4885ERBB4 810/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | EGFR 17/4885ERBB2 23/4885ERBB4 45/4885 |
| US-20100120768-A1 | METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR | NGF, HDGF, SHH | EGFR 85/4885ERBB2 830/4885ERBB4 414/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | EGFR 2171/4885ERBB2 3599/4885ERBB4 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.